Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavituximab + Paclitaxel in Early-Stage TNBC
NCT02685306Phase 2Withdrawn
- Sponsor
- Avid Bioservices, Inc.
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of bavituximab in triple negative breast cancer (TNBC), sponsored by Avid Bioservices, Inc.. Planned start Mar 2016; status: withdrawn.
02
Drugs
bavituximab
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02685306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685306.